MGNX · MacroGenics, Inc.

This transaction represents a strategic divestiture of MacroGenics’ non-core CDMO business to sharpen its focus on clinical-stage oncology therapeutics. The $122.5 million upfront payment provides meaningful non-dilutive capital to accelerate pipeline advancement toward key value inflection points in 2026 and beyond, as stated by CEO Eric Risser. The inclusion of up to $5 million in milestone-based payments introduces modest upside contingent on operational continuity and performance under Bora’s ownership. Critically, the planned manufacturing and supply agreement ensures MacroGenics retains access to clinical drug substance production—preserving development timelines for its internal pipeline without requiring new infrastructure investment. The transfer of ~140 employees and two Maryland facilities (including an FDA-approved 11,000L-capacity site) signals a clean operational handoff, while the sublease arrangement allows MacroGenics temporary continued presence at the Rockville location. Closing remains conditional on customary items—including third-party consents—and timing carries execution risk; delays or failure to close could disrupt near-term capital planning and operational transitions. As disclosed, the Board of Directors of both parties has approved the agreement, reinforcing governance alignment. For investors, this event materially de-risks the company’s capital structure in the near term while refocusing resources on core R&D value drivers—though it eliminates a potential future revenue stream from external CDMO clients.